Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in Chronic Rhinosinusitis With Nasal Polyps
NCT06454240Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of lunsekimig in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Started Jul 2024; status: completed.
02
Drugs
lunsekimig
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06454240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454240.